Healthcare Private Placement and M&A Transactions Review Week Ending January 8 2023

Synthekine: The company raised $100 million of Series C venture funding in a deal led by The Column Group on January 6, 2023. The company is a developer of engineered cytokine therapeutics designed to facilitate disease-optimized treatments.

Ensoma: The company raised $85 million of Series B venture funding in a deal led by 5AM Ventures and Arix Bioscience on January 5, 2023. Alexandria Venture Investments, Takeda Ventures, Bill & Melinda Gates Foundation, SymBiosis Capital Management, Catalio Capital Management, Solasta Ventures, F-Prime Capital, Mirae Asset Global Investments, Cormorant Asset Management, Fred Hutchinson Cancer Research Center, Qatar Investment Authority and Viking Global Investors also participated in the round. The company is an operator of a biotech business intended to develop genomic medicine, pioneering a next-generation in vivo approach for treatment.

Belharra Therapeutics: The company raised $50 million of Series A venture funding from Versant Ventures on January 4, 2023. The company is an operator of an early-stage small molecule discovery company based in San Diego, California.

Volta Medical: The company raised EUR 36 million of Series B venture funding in a deal led by Vensana Capital on January 5, 2023. Gilde Healthcare and Lightstone Ventures also participated in the round. The company is a developer of medical software designed to detect and prevent cardiac diseases arising due to atrial fibrillation.

Immune-Onc Therapeutics: The company raised $25 million of Series B venture funding in a deal led by Triwise Capital on January 5, 2023. Wuxi Biologics, Leukemia & Lymphoma Society, and Proxima Ventures also participated in the round. The company is an operator of a clinical-stage cancer immunotherapy company intended to translate into therapies insights into myeloid cell biology and immune inhibitory receptors.

Onc.AI: The company raised $25 million of Series A venture funding in a deal led by MassMutual Financial Group and Action Potential Venture Capital on January 5, 2023. 515 Ventures, Blue Venture Fund, Accomplice VC, KdT Ventures, Digitalis Ventures, and Life Extension Ventures also participated in the round. The company is a developer of a precision oncology care management platform designed for clinical decision-making.

ISA Pharmaceuticals: The company raised $5 million of venture funding from Cancer Focus Fund on January 4, 2023. The company is a developer of synthetic therapeutic vaccines designed to provide treatment for cancer.

Augustine Therapeutics: The company raised EUR 4. 6 million of venture funding from undisclosed investors on January 3, 2023, putting the company’s pre-money valuation at EUR 5.7 million. The company is a developer of therapeutic drugs designed to treat neuromuscular and neurodegenerative diseases.

Prana Thoracic: The company raised $3.7 million of Series A venture funding in a deal led by New World Angels on January 2, 2023. Texas Medical Center also participated in the round. The company is a manufacturer of medical devices intended to detect and intervene in early-stage lung cancer.

OnLume: The company raised $2.8 million of venture funding from undisclosed investors on January 3, 2023. The company is a developer of an innovative imaging technology designed to advance surgical precision, optimize patient outcomes, and reduce morbidity and costs.

DeuterOncology: The company raised EUR 2.1 million of venture funding from undisclosed investors on January 2, 2023, putting the company’s pre-money valuation at EUR 5.1 million. The company is a developer of MET inhibitors intended to optimize oncology treatments and outcomes.

The Binding Site / Thermo Fisher Scientific: The company was acquired by Thermo Fisher Scientific for GBP 2.25 billion on January 3, 2023. The company is a manufacturer of medical diagnostic products focused on the detection of cancers and immune disorders.

Embody / Zimmer Biomet: The company reached a definitive agreement to be acquired by Zimmer Biomet for an estimated $275 million on January 5, 2023. The company is a developer of implantable medical devices designed to improve the quality of life for sports injury patients.

MGC Diagnostics / CAIRE: The company was acquired by CAIRE, a subsidiary of NGK Spark Plug, for $170.2 million on January 4, 2023. The company is a designer and manufacturer of non-invasive cardiorespiratory diagnostic systems, accessories and consumables for the detection, classification and management of the cardiorespiratory disease.

Cognos Therapeutics / Nocturne Acquisition: The company reached a definitive agreement to acquire Nocturne Acquisition through a reverse merger on January 3, 2023. The company is a developer of diagnostic devices designed to advance the diagnosis and treatment of neuropathic diseases.

LightDeck / Heska: The company was acquired by Heska for $38.7 million on January 2, 2023. The company is a developer of on-the-spot diagnostic products designed to offer fast, accurate, simple, and low-cost diagnostic tests.

OncoBay Clinical / Neuca: The company was acquired by Neuca for $33.5 million on January 3, 2023. The company is an operator of a boutique contract research organization (CRO) designed to provide custom-curated services for clinical trials.

Amryt Pharma / Chiesi Farmaceutici: The company reached a definitive agreement to be acquired by Chiesi Farmaceutici for an undisclosed amount on January 8, 2023. The transaction is expected to close during the first half of 2023. Amryt Pharma PLC is a specialty pharmaceutical company.

Avida Biomed / Agilent Technologies: The company was acquired by Agilent Technologies for an undisclosed amount on January 4, 2023. The company is a developer of novel genomic tools intended to reveal DNA alterations with accuracy for clinical and research use.

Biognosys / Bruker: The company was acquired by Bruker for an undisclosed amount on January 4, 2023. The company is a developer of proteomics tools designed for highly multiplexed protein quantification.

Blacksmith Medicines / Forge Therapeutics: The company reached a definitive agreement to be acquired by Forge Therapeutics for an undisclosed amount on January 2, 2023. The company is a developer of a metalloenzyme chemistry platform designed to develop medicines for immuno-oncology and inflammatory diseases.

MediSked / CaseWorthy: The company was acquired by CaseWorthy, via its financial sponsor STG Partners, through an LBO on January 6, 2023 for an undisclosed amount. The company is a developer of healthcare software solutions designed to support clients within the home and community-based services industry with an integrated, person-centered technology model.

Vyasa Analytics / Certara: The company was acquired by Certara for an undisclosed amount on January 4, 2023. The company is an operator of a deep learning and analytics platform intended for life sciences and healthcare organizations.